All In Biotech

Drug Trial Radar · NCT03874897

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects

Last checked: Nov 19, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

134

Actual

Start

Mar 26, 2019

Primary completion

Mar 20, 2021

Study completion Jan 26, 2024

Sponsor

Lead sponsor
Peking UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CARsgen Therapeutics Co., Ltd.
First posted
Mar 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.

Conditions

  • Advanced Solid Tumor

Interventions

  • CAR-CLDN18.2 T-CellsDrug

    Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses • Chimeric Antigen Receptor T Cells Targeting Claudin18.2

  • PD-1 Monoclonal AntibodyDrug

    Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1

  • ChemotherapyDrug

    First-line systemic therapy according to physician's choice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: 28 days of single infusion
  2. Maximum tolerated dose (MTD)Time frame: 28 days of single infusion

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Department of GI Oncology, Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The First Affiliated Hospital , Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.